PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Center for Translational Bioethics and Health Care Policy and The Steele Institute for Health Innovation, Geisinger Health System, Danville, PA, USA.\', \'Advarra, Columbia, MD, USA.\', \'Department of Medicine, Brigham and Women\'s Hospital and Harvard Medical School, Boston, MA, USA.\', \'Department of Bioethics, Clinical Center, National Institutes of Health, Bethesda, MD, USA.\', \'Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.\', \'Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, PA, USA.\', \'Center for Biomedical Ethics, Stanford University, Stanford, CA, USA.\', \'Indiana University Robert H. McKinney School of Law, Indiana University, Indianapolis, IN, USA.\', \'Biomedical Ethics Program, Division of Health Care Policy Research, Mayo Clinic, Rochester, MN, USA.\', \'Center for Bioethics and Social Sciences in Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.\', \'Berman Institute of Bioethics and Department of Medicine, Johns Hopkins University, Baltimore, MD, USA.\', \'Treuman Katz Center for Pediatric Bioethics, Seattle Children\'s Hospital and Research Institute, Seattle, WA, USA.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1177/1740774520988669
?:hasPublicationType
?:journal
  • Clinical trials (London, England)
is ?:pmid of
?:pmid
?:pmid
  • 33530721
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
?:title
  • An ethics framework for consolidating and prioritizing COVID-19 clinical trials.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all